Advanced Medical Solutions Group Regulatory News (AMS)

30 June 2015

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Pre-Close Trading Update

Winsford, UK, 30 June 2015 - Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, today announces an update on trading prior to its close period for the half year ended 30 June 2015.

The Board confirms that trading for the half year is in line with the Board's expectations and currently expects both revenue and profitability for the full year 2015 to be in line with present market expectations.

Chris Meredith, Chief Executive Officer of AMS, commented: "The Board is pleased with the ongoing good performance of the business. We continue to gain market share with our high quality products by delivering innovation to patients and surgeons."

- Ends -

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc - see www.admedsol.com 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 65 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 470 employees. For more information please see www.admedsol.com.